AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35889747
Drug: Oral Arthrospira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Arthrospira at 3 g daily
Trial: 35889747
Drug: Oral Arthrospira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Arthrospira at 6 g daily
Trial: 32843164
Drug: IND/GLY/MF high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF high-dose (150/50/160 μg) once-daily
Trial: 32843164
Drug: IND/GLY/MF medium-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF medium-dose (150/50/80 μg) once-daily
Trial: 36429797
Drug: Directed vestibular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed vestibular rehabilitation therapy (VRT) plus manual therapy (MT) once a week for 4 weeks
Trial: 36429797
Drug: Directed vestibular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed vestibular rehabilitation therapy (VRT)
Trial: 36429797
Drug: Directed vestibular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed vestibular rehabilitation therapy (VRT) plus manual therapy (MT)
Trial: 37656441
Drug: Cytotoxic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic chemotherapy
Trial: 34599466
Drug: Lactulose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (10 g)
Trial: 35578445
Drug: Pioglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone monotherapy
Trial: 39103966
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT)
Trial: 34717700
Drug: LOV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOV group (tidal volume of 3‐4 ml/kg, respiratory rate of 10‐12 bpm, PEEP of 5‐8 cmH2O, FiO2 30%)
Trial: 34611042
Drug: Partial oral
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial oral antibiotic treatment
Trial: 38960907
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily for 48 weeks
Trial: 32468672
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg bid
Trial: 35132875
Drug: Conventional P2Y12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional P2Y12 inhibitor selection
Trial: 35695197
Drug: Constraint‐Induced Movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐Induced Movement therapy
Trial: 34083234
Drug: Sequential androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential androgen receptor signaling inhibitors (abiraterone and enzalutamide)
Trial: 39312389
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy interventions
Trial: 33470732
Drug: Isometric handgrip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isometric handgrip training (five times weekly)
Trial: 33196410
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control group
Trial: 34901997
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP), approximately 250 mL
Trial: 36196738
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) training consisting of six sessions
Trial: 37689749
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy
Trial: 33459082
Drug: Computerized neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized neurocognitive testing (CNT) administered after maximal physical exertion (MPE) at recovery intervals of Immediate, 10-minutes, and 20-minutes
Trial: 33459082
Drug: Computerized neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized neurocognitive testing (CNT) administered after maximal physical exertion (MPE) at a 20-minute recovery interval
Trial: 33894370
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir therapy (AVT)
Trial: 33894370
Drug: AVT +
RxNorm normalized name: Avtozma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT + adjunctive PDT
Trial: 35030333
Drug: Erdafitinib 8
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib 8 mg/day UpT regimen
Trial: 35843287
Drug: CF only
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF only for 18 hours before CE and simethicone 200mg in 150 ml water immediately prior to CE
Trial: 34424868
Drug: Cost-cutting measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-cutting measures (older-generation implants)
Trial: 35195344
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise program (exercise routines three times weekly and once weekly on discharge for 6 weeks supervised by a physical therapist)
Trial: 34624497
Drug: Tailored chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored chemotherapy (T)
Trial: 34624497
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy (C)
Trial: 36905736
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration
Trial: 35501519
Drug: Laser monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser monotherapy
Trial: 34232082
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing BB‐12 (CAP)
Trial: 36205099
Drug: 50000 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50000 IU/day intramuscular vitamin A for a maximum of two weeks
Trial: 36205099
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued their common treatment protocols
Trial: 33048456
Drug: Glecaprevir/Pibrentasvir (GLE/PIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (GLE/PIB) 300/120 mg
Trial: 35534184
Drug: Hydrocortisone (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (cumulative dose 72.5 mg/kg)
Trial: 32408396
Drug: Methylation-L
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylation-L
Trial: 32635661
Drug: Synbiotic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic preparation
Trial: 36506775
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg midazolam
Trial: 32241084
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with TPF (docetaxel & cisplatin 75 mg/m2 on D1, and fluorouracil 75 mg/m2 on D1-4) followed by CRT (cisplatin 100 mg/m2 on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions)
Trial: 35733373
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (5000 IU daily for 4 months)
Trial: 35733373
Drug: Placebo (topiramate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (topiramate with placebo capsule)
Trial: 35340223
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (Mosapride citrate tablets)
Trial: 34159294
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months adjuvant chemotherapy
Trial: 34159294
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months adjuvant chemotherapy
Trial: 36423412
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (ICBT)
Trial: 32037021
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (12 sessions lasting 2 hours each, 3 follow-up monthly sessions, and 1 closing session)
Trial: 37591293
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg every 3 weeks
Trial: 36308296
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy
Trial: 35948209
Drug: Monthly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly treatment with pegcetacoplan
Trial: 35948209
Drug: Every-other-month (EOM)
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every-other-month (EOM) treatment with pegcetacoplan
Trial: 34274500
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia (TIVA)
Trial: 32013958
Drug: Dapoxetine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine treatment for 4 weeks
Trial: 35005013
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxycodone
Trial: 35167133
Drug: Paraffin cream
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin cream (PC)
Trial: 38985161
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg
Trial: 36782093
Drug: Sotagliflozin 200
RxNorm normalized name: sotagliflozin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotagliflozin 200 mg
Trial: 34117737
Drug: Tocilizumab monotherapy
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab monotherapy
Trial: 34390083
Drug: Amoxicillin-levofloxacin (AL)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-levofloxacin (AL) quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Trial: 34390083
Drug: Tetracycline-levofloxacin (TL)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline-levofloxacin (TL) quadruple therapy
Trial: 34390083
Drug: Amoxicillin-levofloxacin (AL)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-levofloxacin (AL) quadruple therapy
Trial: 33393112
Drug: Lanreotide depot/autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide depot/autogel 120 mg every 4 weeks (LAN)
Trial: 34104096
Drug: Planox® lemon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planox® lemon verbena extract (LVE) 400 mg/human/day
Trial: 33789735
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable soft contact lenses (SCLs)
Trial: 34821020
Drug: Hetrombopag (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag (2.5, 3.75, 5, or 7.5 mg once daily) during Stage 4
Trial: 35177277
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy (CT) in PSOC
Trial: 35177277
Drug: Olaparib (OLA)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (OLA) monotherapy in PROC
Trial: 35177277
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy (CT) in PROC
Trial: 35177277
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy (CT) in BRCA-wildtype PROC
Trial: 33832406
Drug: Aripiprazole at
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole at a dose of up to 20 mg daily
Trial: 33832406
Drug: Quetiapine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine at a dose of up to 600 mg daily
Trial: 33832406
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at a dose of up to 30 mg daily
Trial: 32074243
Drug: Neurohormonal antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neurohormonal antagonists
Trial: 34324783
Drug: Corticosteroids administered
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids administered to PWH (33.3%)
Trial: 33645135
Drug: Shenxiong Injection
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenxiong Injection combined with conventional treatment
Trial: 33645135
Drug: Honghua Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honghua Injection combined with conventional treatment
Trial: 32471400
Drug: A Healthy
RxNorm normalized name: Neutrogena Healthy Scalp Conditioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Healthy Generation programme (physical activity and healthy meals/fruit twice a week from August to May)
Trial: 32331079
Drug: Dasotraline (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline (4-8 mg/d)
Trial: 35304391
Drug: Monthly online
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly online ePROM symptom reporting
Trial: 37368349
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV)
Trial: 32107360
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all 3 antagonists (BCTC, A‐967079, amiloride)
Trial: 32281732
Drug: Diet soda
RxNorm normalized name: Magadi soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet soda containing sucralose and acesulfame‐potassium (Ace‐K) consumed three times daily for 8 weeks
Trial: 35045221
Drug: Chemotherapy (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin at 60 mg/m² every 3 weeks or paclitaxel at 80 mg/m² weekly)
Trial: 34108078
Drug: Sufentanil 1.91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1.91 μg (ED90)
Trial: 34108078
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 μg (recommended dosage)
Trial: 33303468
Drug: Functional avoidance
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional avoidance radiation therapy
Trial: 35315622
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion
Trial: 32439205
Drug: Pseudomonas aeruginosa
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa spray
Trial: 35440940
Drug: Routine oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oxygen therapy combined with NIV (low flow conventional oxygen therapy + NIV)
Trial: 35440940
Drug: Routine oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oxygen therapy combined with NIV
Trial: 33472779
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with knowledge of hypertension consequences and treatment options
Trial: 33472779
Drug: Individuals who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals who believed BP medications should be stopped from time to time
Trial: 33472779
Drug: Individuals who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals who reported not taking daily treatment
Trial: 33472779
Drug: Individuals listing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals listing BP medications as the most effective way to reduce BP
Trial: 32280083
Drug: Oral omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Trial: 36095308
Drug: Progesterone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (up to 400 mg/day)
Trial: 35126618
Drug: Tuina therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuina therapy
Trial: 34270348
Drug: MIBG +
RxNorm normalized name: mIBG
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIBG + Vincristine (IV on day 0) + Irinotecan (daily on days 0-4)
Trial: 34270348
Drug: MIBG +
RxNorm normalized name: mIBG
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIBG + Vorinostat (180 mg/m2/dose orally once daily on days 1 to 12)
Trial: 32690001
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) - single dose (wavelength 830nm, energy 2J/point) applied at four points (2 buccal, 2 palatal) for each maxillary anterior tooth root.
Trial: 32690001
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment - same application procedure without emitting the laser beam.
Trial: 35422183
Drug: Glyphosate low
RxNorm normalized name: glyphosate
DrugBank: Glyphosate (DB04539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate low dose of 7.2 g a.e. ha‐1
Trial: 35422183
Drug: Glyphosate low
RxNorm normalized name: glyphosate
DrugBank: Glyphosate (DB04539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate low dose of 108.0 g a.e. ha‐1
Trial: 35633275
Drug: Solriamfetol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 300 mg/day
Trial: 32250572
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care tablet containing kiwifruit powder (Intervention II)
Trial: 32250572
Drug: Three oral
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three oral care tablets (Intervention III)
Trial: 32585854
Drug: Almega®PL (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almega®PL (1 g/day)
Trial: 36071165
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy matched to genomic alteration
Trial: 34538087
Drug: Monitoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring group (platelet function monitoring-guided adjustment of antiplatelet therapy)
Trial: 37257216
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg/day for 14 days, then tapered to 10 mg for 1 month, followed by 5 mg/day for 2 months.
Trial: 37257216
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg/day for 14 days, then tapered to 5 mg for 2 months.
Trial: 34444526
Drug: Variable-rate feedback
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable-rate feedback infusion (VFIM) of fentanyl/ropivacaine, basal infusion rate adjusted by 0.5 mL/h increase and 0.3 mL/h decrease
Trial: 34444526
Drug: Conventional fixed-rate
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fixed-rate basal infusion (CFIM) of fentanyl/ropivacaine, fixed basal infusion rate of 5 mL/h
Trial: 32234755
Drug: AZD9496 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9496 250 mg twice daily for 5-14 days
Trial: 32234755
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg on day 1
Trial: 38101250
Drug: Treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual
Trial: 32751219
Drug: High polyphenol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High polyphenol olive oil (HPOO) - 60 mL/day (360 mg/kg polyphenols)
Trial: 32751219
Drug: Low polyphenol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low polyphenol olive oil (LPOO) - 60 mL/day (86 mg/kg polyphenols)